Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose oral clarithromycin salvage therapy in relapsed or refractory extranodal marginal zone lymphoma
2011-004808-37Phase 2Terminated
- Sponsor
- Fondazione Centro San Raffaele
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clarithromycin in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by Fondazione Centro San Raffaele. Primary endpoints: Overall response rate, Complete response rate and 1 more. Started Dec 2011; status: terminated.
02
Drugs
clarithromycin
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2011-004808-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004808-37.